类风湿关节炎的生物治疗:临床综述。

IF 3.4 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Biologics : Targets & Therapy Pub Date : 2021-08-12 eCollection Date: 2021-01-01 DOI:10.2147/BTT.S252575

Kate E Findeisen, Julia Sewell, Andrew J K Ostor

{"title":"类风湿关节炎的生物治疗:临床综述。","authors":"Kate E Findeisen, Julia Sewell, Andrew J K Ostor","doi":"10.2147/BTT.S252575","DOIUrl":null,"url":null,"abstract":"Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the \"real-world\" use of bDMARDs and how they fit into the overall RA treatment guidelines.","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":" ","pages":"343-352"},"PeriodicalIF":3.4000,"publicationDate":"2021-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/59/btt-15-343.PMC8370108.pdf","citationCount":"15","resultStr":"{\"title\":\"Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician.\",\"authors\":\"Kate E Findeisen, Julia Sewell, Andrew J K Ostor\",\"doi\":\"10.2147/BTT.S252575\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the \\\"real-world\\\" use of bDMARDs and how they fit into the overall RA treatment guidelines.\",\"PeriodicalId\":9025,\"journal\":{\"name\":\"Biologics : Targets & Therapy\",\"volume\":\" \",\"pages\":\"343-352\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2021-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/59/btt-15-343.PMC8370108.pdf\",\"citationCount\":\"15\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biologics : Targets & Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/BTT.S252575\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biologics : Targets & Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/BTT.S252575","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 15

摘要

类风湿性关节炎(RA)是一种以滑膜关节炎症为特征的疾病，对个人和社会都造成了沉重的医疗负担。随着生物疾病修饰抗风湿药物(bDMARDs)的引入，类风湿性关节炎治疗领域发生了最重大的变化之一。目前可获得的bdmard有五类，每一类都有不同的分子靶点，其疗效和安全性也存在细微差异。这篇综述还描述了bDMARDs在“现实世界”中的应用，以及它们如何适应RA的总体治疗指南。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician.

Rheumatoid arthritis (RA) is a disease characterised by inflammation of synovial joints and poses a substantial healthcare burden on both the individual and society. One of the most significant shifts in the RA therapeutic landscape has occurred with the introduction of biological disease modifying anti-rheumatic drugs (bDMARDs). There are five classes of bDMARDs currently available, each with a different molecular target and subtle differences in their efficacy and safety profile. This review also describes the "real-world" use of bDMARDs and how they fit into the overall RA treatment guidelines.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biologics : Targets & Therapy MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

8.30

自引率

0.00%

发文量

审稿时长

16 weeks